TRAMADOL-ACET TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
12-12-2018
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE
Tillgänglig från:
PRO DOC LIMITEE
ATC-kod:
N02AJ13
INN (International namn):
TRAMADOL AND PARACETAMOL
Dos:
325MG; 37.5MG
Läkemedelsform:
TABLET
Sammansättning:
ACETAMINOPHEN 325MG; TRAMADOL HYDROCHLORIDE 37.5MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
Narcotic (CDSA I)
Terapiområde:
OPIATE AGONISTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0250601001; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2019-09-11
Produktens egenskaper
Page
1
of
65
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TRAMADOL-ACET
tramadol hydrochloride and acetaminophen tablets, USP
37.5 mg tramadol hydrochloride/325 mg acetaminophen
Centrally Acting Analgesic
PRO DOC LTÉE
Date of Revision:
2925, boul. Industriel
December 12, 2018
Laval, Quebec
H7L 3W9
SUBMISSION CONTROL NUMBER: 221949
Page
2
of
65
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................ 3
SUMMARY PRODUCT INFORMATION
........................................................... 3
INDICATIONS AND CLINICAL USE
................................................................ 3
CONTRAINDICATIONS
..................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................... 4
ADVERSE REACTIONS
.................................................................................
17
DRUG INTERACTIONS
.................................................................................
21
DOSAGE AND ADMINISTRATION
................................................................ 25
OVERDOSAGE
.............................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
................................................ 29
STORAGE AND STABILITY
..........................................................................
36
SPECIAL HANDLING INSTRUCTIONS
....................................................... 37
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................... 37
PART II: SCIENTIFIC INFORMATION
................................................................. 38
PHARMACEUTICAL INFORMATION
............................................................ 38
CLINICAL TRIALS
........................................................................................
39
DETAILED PHARMACOLOGY
......................................................................
43
TOXICOLOGY...............................
Läs hela dokumentet
